Related Experiment Videos
Aromatase inhibitors: current status
1Department of Breast and Gynecology Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review. Source of estrogen in the human body and means of its ablation are discussed with emphasis on aromatase inhibition. Aminoglutethimide was highlighted as the prototype for inhibition of aromatase. All other agents that have aromatase inhibitory effect, as well as, antitumor effect were discussed in reference to their structure, chemistry, pharmacology, and pharmacokinetics in animals and humans. Their respective antitumor effect in experimental studies and humans, including dose-schedules responses and side effects, are also reviewed. New aromatase inhibitors have significant antitumor activity in breast cancer and may have better therapeutic index than currently available drugs.
Insights
Newer aromatase inhibitors show significant antitumor activity for metastatic breast cancer treatment. These agents may offer a better therapeutic index compared to existing drugs.
Area of Science:
- Oncology
- Pharmacology
Background:
- Estrogen is a key driver in many breast cancers.
- Aromatase inhibitors block estrogen production, a crucial therapeutic strategy.
Purpose of the Study:
- To review aromatase inhibitors for metastatic breast cancer.
- Focus on newer agents and their development.
Main Methods:
- Literature review of English articles from the past 5 years.
- Searches conducted using Med-Line and Cancer-Line databases.
Main Results:
- Aminoglutethimide identified as a prototype aromatase inhibitor.
- Newer agents demonstrate significant antitumor activity.
- Evaluation of structure, chemistry, pharmacology, pharmacokinetics, and antitumor effects.
Conclusions:
- New aromatase inhibitors possess substantial antitumor activity in breast cancer.
- These novel agents may provide an improved therapeutic index over current treatments.